

StageZero Announces 2020 Year End Analyst and Investor Call

written by Igor Makarov | March 31, 2021

March 31, 2021 ([Source](#)) – StageZero Life Sciences (“StageZero” or the “Company”) (TSX:SZLS) today announced that it will release its Fourth Quarter 2020 and Year End operational results after market close on Wednesday March 31, 2021. StageZero’s Chairman and CEO, James R Howard-Tripp, will host a conference call and online presentation at 8:30 am ET on Thursday April 1, 2021 to review the operational results and discuss business developments for the period and to date.

Analyst and Investor Call

Event Date: Thursday April 1, 2021

Time: 8:30 AM ET

Webcast Link: <https://www.webcaster4.com/Webcast/Page/2082/40528>

Participant Numbers: Toll Free: 877-407-8031

International: 201-689-8031

Replay Number: Toll Free: 877-481-4010

International: 919-882-2331

Replay Passcode: 40528

About StageZero Life Sciences, Ltd.

StageZero Life Sciences is dedicated to the early detection of multiple disease states through whole blood. The Company operates a CAP accredited and CLIA certified high complexity reference laboratory based in Richmond, Virginia. A specialist in PCR testing for the early identification of Cancer through blood, the Company is uniquely positioned to provide both COVID PCR testing (swab and saliva) and blood test analysis (Antibody

testing). Our full service, telehealth platform includes access to physicians and phlebotomists who can prescribe and draw samples for individuals and groups. As we provide COVID-19 test during this Pandemic, we continue making progress with our mission to eradicate late stage cancers through early detection. Our next generation test, Aristotle®, is a multi-cancer panel for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer. www.stagezerolifesciences.com

Company Contacts:

James R. Howard-Tripp
Chairman & CEO

Rebecca Greco
Investor Relations
rgreco@stagezerols.com

Tel: 1-855-420-7140 Ext. 1838

SOURCE: StageZero Life Sciences Ltd